Please sign in to follow a disease.
Pterygium
MONDO:0005085A wedge-shaped fibrovascular lesion arising from the bulbar conjunctiva and extending to the cornea. It is caused by chronic exposure to solar ultraviolet radiation, heat, and dust. It may cause severe vision loss. Studies have linked pterygium to neoplastic proliferation and suggest that it may be a stem cell disorder.
Also known as: pterygium of conjunctiva and cornea
1467 clinical trials for this condition and its sub-types, 16 tagged with Pterygium itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pterygium
-
Conjunctival pterygium 5 trials
1 sub-type
-
Double pterygium 0 trials
Most studied deeper sub-types
-
Could donated tissue help heal stubborn wounds? new study investigates
Disease control OngoingThis early-stage study is testing whether a specially prepared membrane made from donated human tissue can help heal chronic wounds, like diabetic foot ulcers and eye surface injuries. The membrane is sterilized with different doses of radiation to find the best balance between s…
Phase 1 • Sponsor: Libyan Center for Biotechnology Research • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Surfer's eye surgery may sharpen vision by reshaping cornea
Disease control By invitation onlyThis study looks at how removing a pterygium (a fleshy growth on the eye) and replacing it with a small piece of the patient's own eye tissue changes the shape of the cornea. Researchers will measure the cornea's curve before and one month after surgery in 130 adults aged 30 to 7…
Sponsor: Mughal Eye Trust Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New eye drop could stop pterygium growth without surgery
Disease control OngoingThis Phase 3 trial tests CBT-001 eye drops against a placebo in 660 people with pterygium, a non-cancerous growth on the eye's surface. The goal is to see if the drops can reduce redness and stop the growth from getting bigger over 24 months. If successful, it could offer a drug-…
Phase 3 • Sponsor: Cloudbreak Therapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC